🧬 How Biotech Companies Get Debt Funding (Without Revenue) | Parag Shah Re-Release (1/2)

🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science.

As a TBSP listener, you can get exclusive perks through Excedr’s partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners.

"I was fortunate that my parents pretty much allowed for a more experimental, open approach to education being important, but do what you want to do, right? Try different things, take healthy risks."

We’re revisiting some of our previous episodes over the holidays this year. Our first rerelease is part 1 of this episode of The Biotech Startups Podcast with Parag Shah, where we explore his remarkable journey from molecular biologist to CEO and Founding Managing Director of K2 Health Ventures. Parag shares how his upbringing in New York City with immigrant parents who encouraged experimentation shaped his entrepreneurial mindset, and describes the pivotal moment when he realized bench science wasn't his calling while researching at MIT's Whitehead Institute.​​

The conversation reveals how Parag boldly proposed building Imperial Bank's life sciences lending practice from scratch, despite being young and relatively inexperienced. He discusses lessons learned from MIT about persistence through failure, translating traditional credit frameworks to venture-backed biotech companies, and the complementary role of debt capital alongside equity financing in life sciences.

Key topics covered:

If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening.

Apple:https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994

Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4

Youtube: https://www.youtube.com/@thebiotechstartupspodcast 

Website: https://www.thebiotechstartupspodcast.com/ 

https://www.linkedin.com/in/paragshah333/ 

https://k2hv.com/ 

 

LinkedIn: https://www.linkedin.com/in/jonchee

LinkedIn: https://www.linkedin.com/company/excedr/ 

Website: https://www.excedr.com

Website: https://flow.page/kyojin 

Biotech Startup Fundraising: https://www.excedr.com/resources/biotech-startup-funding-options

Venture Debt Financing https://www.excedr.com/blog/venture-debt-for-biotech-startups-overview 

Venture Capital and Venture Debt Relationship: https://dealroom.net/faq/venture-debt-financing 

The Human Genome Project https://www.genome.gov/human-genome-project 

MIT (Massachusetts Institute of Technology): https://www.mit.edu​ 

Whitehead Institute for Biomedical Research: https://wi.mit.edu​ 

Comerica Bank: https://www.comerica.com ​

Hercules Capital: https://www.htgc.com 

Larry Suskind: https://dusp.mit.edu/people/lawrence-susskind 

John Ehrenfeld: https://www.linkedin.com/in/johnehrenfeld/ 

Timestamps:

00:00 Intro

02:44 Upbringing in New York City and Parents' Influence

05:19 Early Science Teachers and Inspiration

09:31 Choosing MIT and Meeting His Wife

10:54 MIT's Rigor and Learning to Persist

13:09 Fraternity Experience and Building Diverse Connections

14:34 Undergraduate Research at the Whitehead Institute

17:46 Pursuing Environmental Policy and Graduate School

21:34 From Environmental Policy to Banking in Argentina

25:45 Bank Boston's Credit Training Program

32:39 Embracing Uncertainty and Being Willing to Fail

37:51 Building Imperial Bank's Life Sciences Credit Framework

41:32 The Role of Debt vs. Equity in Biotech Financing

45:44 Outro

The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.